Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGiving a weight loss injection in the stomach is one of three licensed sites, and the stomach is the spot most people choose first. Side effects from injecting there are mostly the same as those from any site — nausea, digestive discomfort, occasional local reactions — but knowing what to expect, and what to watch for, makes a real difference to how you manage them. These are prescription-only medicines: a prescriber assesses your suitability and talks through side effects before treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a common worry, and an understandable one. If the injection goes into the abdomen and the abdomen is where the discomfort is felt, it's natural to assume one caused the other. The reality is gentler than that: the gastrointestinal effects of medicines like tirzepatide (Mounjaro) and semaglutide (Wegovy) are pharmacological, not site-specific. They happen because both medicines slow how quickly food leaves the stomach and act on appetite centres in the brain, not because of where the needle went in.
The three licensed injection sites are the abdomen, the thigh and the upper arm. The NHS medicines page for tirzepatide confirms you should rotate between sites; it does not suggest one triggers more systemic side effects than another. So if you feel nauseous after your first pen, the stomach injection isn't the cause. Your digestive system is adjusting to the medicine itself.
Local reactions at the injection site (a small red patch, mild puffiness, brief tenderness) are separate from systemic GI effects and are usually gone within 48 hours. If you're finding the abdomen uncomfortable, the thigh or upper arm are equally valid. What matters is rotating sites each week to avoid tissue build-up. You can read more about injecting into the stomach correctly if technique is something you want to revisit.
The most frequently reported side effects across both licensed weight loss injection options are gastrointestinal: nausea is the most common, followed by loose stools or diarrhoea, constipation, burping, indigestion and reflux. Fatigue and headache appear less often but are documented. According to the NHS and the medicines' Summary of Product Characteristics, these effects are typically strongest in the first few weeks of treatment and after each dose increase, then ease as the body adapts.
A few practical things tend to help (eating smaller portions, avoiding very fatty or spicy meals around injection day, staying well hydrated) though personal plans should come from your prescriber or a dietitian rather than a general page. The full side-effect profile of weight loss injections covers both medicines in more detail if you want to compare them side by side.
One point worth making plainly: most people who experience nausea find it manageable, not disabling. It doesn't mean the medicine is harming you. That said, if vomiting is severe enough to prevent you keeping fluids down, contact your prescriber or NHS 111, dehydration can cause its own complications, particularly for kidney function.
Most GI side effects pass. Some need prompt attention. The MHRA issued a specific safety communication in January 2026 highlighting acute pancreatitis as a known, infrequent but potentially serious effect of GLP-1 medicines. The signal to act is severe stomach pain, pain that is persistent, doesn't settle with rest, and may radiate through to the back, with or without vomiting. That pattern needs same-day assessment, not monitoring at home.
Other situations that warrant medical contact rather than waiting: signs of an allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid heartbeat), significant dizziness or fainting, and any injection-site reaction that is spreading, warm to touch or not improving after a few days. The MHRA Yellow Card scheme lets you report side effects you experience, and those reports directly inform ongoing safety monitoring, it takes about five minutes online.
For a broader picture of what the licensed once-weekly injections involve day-to-day, the once-weekly injection guide covers the routine and what to expect over the first months. If you're also researching other types of injections you may have seen advertised (B12, or so-called stomach botox) their side-effect profiles are quite different, and the evidence base is not comparable; see our pages on B12 injection side effects and stomach botox for weight loss for context.
Side effects don't come as a surprise to a prescriber who knows your health history. Part of the clinical consultation is going through your current medicines, your medical history and any conditions that could make certain side effects more significant for you, a history of gallstones, for example, or a GI condition that would make prolonged nausea harder to manage safely.
At nume, every consultation is read by a GPhC-registered Independent Prescriber (a named clinician, not automated scoring) who can flag individual risk factors and adjust the treatment plan accordingly. There's no 12-week wait for that conversation. If side effects do emerge once treatment is underway, aftercare is available seven days a week. The treatment consultation page explains how the process works from start to finish.
Prescription medicines licensed for weight management, whether tirzepatide or semaglutide, have well-characterised safety profiles built from large clinical trials. That characterisation matters. It means that when something unexpected comes up, there's a framework for deciding whether it fits the known pattern or needs investigation. That's a different situation from treatments with thinner evidence behind them. Our clinical team is glad to discuss what's relevant to your specific situation as part of the free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.